Management of community-associated methicillin-resistant Staphylococcus aureus infections in children

Pharmacotherapy

Volumn 26, Issue 12 I, 2006, Pages 1758-1770

  Le, Jennifer ^a   Lieberman, Jay M ^b,c  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^b MILLER CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Children; Community acquired methicillin resistant Staphylococcus aureus; Community associated methicillin resistant Staphylococcus aureus; Pediatrics

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DOXYCYCLINE; ERYTHROMYCIN; GENTAMICIN; LINCOSAMIDE; LINEZOLID; METICILLIN; MIKAMYCIN B; MINOCYCLINE; NAFCILLIN; OXACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SEROTONIN UPTAKE INHIBITOR; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN;

ABDOMINAL PAIN; AGRANULOCYTOSIS; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTHRALGIA; BACTEREMIA; BLOOD DYSCRASIA; BONE MARROW SUPPRESSION; CLINICAL FEATURE; COCHRANE LIBRARY; COMMUNICABLE DISEASE; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DISCOLORATION OF BODY FLUID; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMPYEMA; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATITIS; HUMAN; HYPERBILIRUBINEMIA; HYPERSENSITIVITY REACTION; INFECTION PREVENTION; INFECTION RISK; INJECTION SITE REACTION; JAUNDICE; LIVER TOXICITY; MEDLINE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; NAUSEA; NEPHROTOXICITY; NONHUMAN; OSTEOMYELITIS; OTOTOXICITY; PAIN; PENICILLIN RESISTANCE; PHLEBITIS; PIGMENT DISORDER; PNEUMONIA; PREVALENCE; PRIMARY PREVENTION; PSEUDOMEMBRANOUS COLITIS; RASH; RECOMMENDED DRUG DOSE; RED MAN SYNDROME; REVIEW; RISK FACTOR; SEROTONIN SYNDROME; SIDE EFFECT; SINGLE DRUG DOSE; SKIN INFECTION; STAPHYLOCOCCUS INFECTION; STEVENS JOHNSON SYNDROME; SYSTEMATIC REVIEW; TENDERNESS; THROMBOCYTOPENIA; URINARY TRACT INFECTION; VENOUS IRRITATION; VOMITING;

ANTI-BACTERIAL AGENTS; CHILD; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; METHICILLIN RESISTANCE; PREVALENCE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 33845363001     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.12.1758     Document Type: Review

References (130)

1. Chambers HF. The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis 2001;7:178-82.
2. Centers for Disease Control and Prevention. Four pediatric deaths from community-associated methicillin-resistant Staphylococcus aureus - Minnesota and North Dakota, 1997-1999. MMWR Morbid Mortal Wkly Rep 1999;48:707-10.
3. Kirby W. Extraction of a highly potent penicillin inactivator from penicillin resistant staphylococci. Science 1944;99:452-3.
4. Jessen O, Rosendal K, Bulow P, Faber V, Eriksen KR. Changing staphylococci and staphylococcal infections: a ten-year study of bacteria and cases of bacteremia. N Engl J Med 1969;281:627-35.
5. Hospital Infections Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Public Health Service, U.S. Department of Health and Human Services. National nosocomial infections surveillance (NNIS) system report, data summary from January 1990-May 1999, issued June 1999. Am J Infect Control 1999;27:520-32.
6. Rathore MH, Kline MW. Community-associated methicillin-resistant Staphylococcus aureus infections in children. Pediatr Infect Dis J 1989;8:645-7.
7. Herold BC, Immergluck LC, Maranan MC, et al. Community-associated methicillin-resistant Staphylococcus aureus infections in children with no predisposing risk. JAMA 1998;279:593-8.
8. Frank AL, Marcinak JF, Mangat PD, Schreckenberger PC. Community-associated and clindamycin-susceptible methicillin-resistant Staphylococcus aureus in children. Pediatr Infect Dis J 1999;18:993-1000.
9. Gorak FJ, Yamada SM, Brown JD. Community-associated methicillin-resistant Staphylococcus aureus in hospitalized adults and children without known risk factors. Clin Infect Dis 1999;29:797-800.
10. Fergie JE, Purcell K. Community-associated methicillin-resistant Staphylococcus aureus infections in south Texas children. Pediatr Infect Dis J 2001;20:860-3.
11. Sattler CA, Mason EO Jr, Kaplan SL. Prospective comparison of risk factors and demographic and clinical characteristics of community-associated, methicillin-resistant versus methicillin-susceptible Staphylococcus aureus infection in children. Pediatr Infect Dis J 2002;21:910-17.
12. Johnigan RH, Pereira KD, Poole MD. Community-associated methicillin-resistant Staphylococcus aureus in children and adolescents: changing trends. Arch Otolaryngol Head Neck Surg 2003;129:1049-52.
13. Dietrich DW, Auld DB, Mermel LA. Community-associated methicillin-resistant Staphylococcus aureus in southern New England children. Pediatrics 2004;113:E347-52.
14. Buckingham SC, McDougal LK, Cathey LD, et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus at a Memphis, Tennessee children's hospital. Pediatr Infect Dis J 2004;23:619-24.
15. Purcell K, Fergie J. Epidemic of community-acquired methicillin-resistant Staphylococcus aureus infections: a 14-year study at Driscoll Children's Hospital. Arch Pediatr Adolesc Med 2005;159:980-5.
16. Hussain FM, Boyle-Vavra S, Bethel CD, Daum RS. Current trends in community-associated methicillin-resistant Staphylococcus aureus at a tertiary care pediatric facility. Pediatr Infect Dis J 2000;19:1163-6.
17. Adcock PM, Pastor P, Medley F, Patterson JE, Murphy TV. Methicillin-resistant Staphylococcus aureus in two child care centers. J Infect Dis 1998;178:577-80.
18. Lindenmayer JM, Schoenfeld S, O'Grady R, Carney JK. Methicillin-resistant Staphylococcus aureus in a high school wrestling team and the surrounding community. Arch Intern Med 1998;158:895-9.
19. Shahin R, Johnson IL, Jamieson F, McGeer A, Tolkin J, Ford-Jones EL. Methicillin-resistant Staphylococcus aureus carriage in a child care center following a case of disease. Toronto child care center study group. Arch Pediatr Adolesc Med 1999;153:864-8.
20. Nguyen DM, Mascola L, Brancoft E. Recurring methicillin-resistant Staphylococcus aureus infections in a football team. Emerg Infect Dis 2005;11:526-32.
21. Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005;352:1436-44.
22. Pan ES, Diep BA, Carleton HA, et al. Increasing prevalence of methicillin-resistant Staphylococcus aureus infection in California jails. Clin Infect Dis 2003;37:1384-8.
23. Centers for Disease Control and Prevention. Methicillin-resistant Staphylococcus aureus infections in correctional facilities - Georgia, California, and Texas, 2001-2003. MMWR Morb Mortal Wkly Rep 2003;52:992-6.
24. Baillargeon J, Kelley MF, Leach CT, Baillargeon G, Pollock BH. Methicillin-resistant Staphylococcus aureus infection in the Texas prison system. Clin Infect Dis 2004;38:e92-5.
25. Kluytmans J, van Belkum A, Verbrugh H. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev 1997;10:505-20.
26. Kuehnert MJ, Kruszon-Moran D, Hill HA, et al. Prevalence of Staphylococcus aureus nasal colonization in the United States, 2001-2002. J Infect Dis 2006;193:172-9.
27. Nakamura MM, Rohling KL, Shashaty M, Lu H, Tang YW, Edwards KM. Prevalence of methicillin-resistant Staphylococcus aureus nasal carriage in the community pediatric population. Pediatr Infect Dis J 2002;21:917-22.
28. Hidron AI, Kourbatova EV, Halvosa JS, et al. Risk factors for colonization with methicillin-resistant Staphylococcus aureus (MRSA) in patients admitted to an urban hospital: emergence of community-associated MRSA nasal carriage. Clin Infect Dis 2005;41:159-66.
29. Groom AV, Wolsey DH, Naimi TS, et al. Community-acquired methicillin-resistant Staphylococcus aureus in a rural American Indian community. JAMA 2001;286:1201-5.
30. Baggett HC, Hennessy TW, Leman R, et al. An outbreak of community-onset methicillin-resistant Staphylococcus aureus skin infections in southwestern Alaska. Infect Control Hosp Epidemiol 2003;24:397-402.
31. Hill PC, Birch M, Chambers S, et al. Prospective study of 424 cases of Staphylococcus aureus bacteremia: determination of factors affecting incidence and mortality. Intern Med J 2001;31:97-103.
32. Centers for Disease Control and Prevention. Community-associated methicillin-resistant Staphylocoecus aureus infections in Pacific Islanders - Hawaii, 2001-2003. MMWR Morb Mortal Wkly Rep 2004;53:767-70.
33. Salgado CD, Farr BM, Calfee DP. Community-acquired methicillin-resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors. Clin Infect Dis 2003;36:131-9.
34. Charlebois ED, Perdreau-Remington F, Kreiswirth B, et al. Origins of community strains of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2004;39:47-54.
35. Ma XX, Ito T, Tiensasitorn C, et al. Novel type of staphylococcal cassette chromosome mec identified in community-acquired methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 2002;46:1147-52.
36. Daum RS, Ito T, Hiramatsu K, et al. A novel methicillin-resistance cassette in community-acquired methicillin-resistant Staphylococcus aureus isolates of diverse genetic backgrounds. J Infect Dis 2002;186:1344-7.
37. Okuma K, Iwakawa K, Turnidge JD, et al. Dissemination of new methicillin-resistant Staphylococcus aureus clones in the community. J Clin Microbiol 2002;40:4289-94.
38. Weber JT. Community-associated methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2005;41:S269-72.
39. Naimi TS, LeDell KH, Como-Sabetti K, et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003;290:2976-84.
40. Sanchez ML, Flint KK, Jones RN. Occurrence of macrolide-lincosamide- streptogramin resistance among staphylococcal clinical isolates at a university medical center: is false susceptibility to new macrolides and clindamycin a contemporary clinical and in vitro testing problem? Diagn Microbiol Infect Dis 1993;16:205-13.
41. Panagea S, Perry JD, Gould FK. Should clindamycin be used in treatment of patients with infections caused by erythromycin-resistant staphylococci? J Antimicrob Chemother 1999;44:581-2.
42. Frank AL, Marcinak JF, Mangat PD, et al. Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr Infect Dis J 2002;21:530-4.
43. Siberry GK, Tekle T, Carroll K, Dick J. Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin Infect Dis 2003;37:1257-60.
44. Leclercq R, Courvalin P. Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification. Antimicrob Agents Chemother 1991;35:1267-72.
45. Kaplan SL, Hulten KG, Gonzalez BE, et al. Three-year surveillance of community-acquired Staphylococcus aureus infections in children. Clin Infect Dis 2005;40:1785-91.
46. Martinez-Aguilar G, Hammerman W, Mason EO Jr, Kaplan SL. Clindamycin treatment of invasive infections caused by community-associated, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children. Pediatr Infect Dis J 2003;22:593-8.
47. Chavez-Bueno S, Bozdogan B, Katz K, et al. Inducible clindamycin resistance and molecular epidemiologic trends of pediatric community-acquired methicillin-resistant Staphylococcus aureus in Dallas, Texas. Antimicrob Agents Chemother 2005;49:2283-8.
48. Lina G, Piemont Y, Godail-Gamot F, et al. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 1999;29:1128-32.
49. Martinez-Aguilar G, Avalos-Mishaan A, Hulten K, Hammerman W, Mason EO Jr, Kaplan SL. Community-acquired, methicillin-resistant and methicillin- susceptible Staphylococcus aureus musculoskeletal infections in children. Pediatr Infect Dis J 2004;23:701-6.
50. Prevost G, Couppie P, Prevost P, et al. Epidemiological data on Staphylococcus aureus strains producing synergohymenotropic toxins. J Med Microbiol 1995;42:237-45.
51. Gonzalez BE, Hulten KG, Dishop MK, et al. Pulmonary manifestations in children with invasive community-acquired Staphylococcus aureus infection. Clin Infect Dis 2005;41:583-90.
52. Daum RS. Community-acquired methicillin-resistant Staphylococcus aureus infections. Pediatr Infect Dis J 1998;17:745-6.
53. Gillet Y, Issartel B, Vanhems P, et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 2002;359:753-9.
54. Miller LG, Perdreau-Remington F, Rieg G, et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med 2005;352:1445-53.
55. Kravitz GR, Dries DJ, Peterson ML, Schlievert PM. Purpura fulminans due to Staphylococcus aureus. Clin Infect Dis 2005;40:941-7.
56. Ochoa TJ, Mohr J, Wanger A, Murphy JR, Heresi GP. Community-associated methicillin-resistant Staphylococcus aureus in pediatric patients. Emerg Infect Dis 2005;11:966-8.
57. Lee MC, Rios AM, Aten MF, et al. Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin- resistant Staphylococcus aureus. Pediatr Infect Dis J 2004;23:123-7.
58. Gonzalez BE, Martinez-Aguilar G, Hulten KG, et al. Severe staphylococcal sepsis in adolescents in the era of community-acquired methicillin-resistant Staphylococcus aureus. Pediatrics 2005;115:642-8.
59. Healy CM, Hulten KG, Palazzi DL, Campbell JR, Baker CJ. Emergence of new strains of methicillin-resistant Staphylococcus aureus in a neonatal intensive care unit. Clin Infect Dis 2004;39:1460-6.
60. Yeldandi V, Strodtman R, Lentino JR. In-vitro and in-vivo studies of trimethoprim-sulphamethoxazole against multiple resistant Staphylococcus aureus. J Antimicrob Chemother 1988;22:873-80.
61. Al-Shawwa BA, Wegner D. Trimethoprim-sulfamethoxazole plus topical antibiotics as therapy for acute otitis media with otorrhea caused by community-acquired methicillin-resistant Staphylococcus aureus in children. Arch Otolaryngol Head Neck Surg 2005;131:782-4.
62. Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med 1992;117:390-8.
63. Adra M, Lawrence KR. Trimethoprim-sulfamethoxazole for treatment of severe Staphylococcus aureus infections. Ann Pharmacother 2004;38:338-41.
64. Masters PA, O'Bryan TA, Zurlo J, Miller DQ, Joshi N. Trimethoprim- sulfamethoxazole revisited. Arch Intern Med 2003;163:402-10.
65. George JN, Raskob GE, Shah SR, et al. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med 1998;129:886-90.
66. Avenlis Pharmaceuticals. Rifadin (rifampin) package insert. Bridgewater, NJ; 2004.
67. Munckhof WJ, Kleinschmidt SL, Turnidge JD. Resistance development in community-acquired strains of methicillin-resistant Staphylococcus aureus: an in vitro study. Int J Antimicrob Agents 2004;24:605-8.
68. Centers for Disease Control and Prevention. Recommendations for preventing the spread of vancomycin resistance. Recommendations of the hospital infection control practices advisory committee (HICPAC). MMWR Recomm Rep 1995;44:1-13.
69. Fowler VG Jr, Scheld WM, Bayer AS. Endocarditis and intravascular infections. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases, 6th ed. Philadelphia: Elsevier, Inc., 2005:998-9.
70. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999;340:493-501.
71. Fridkin SK. Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know. Clin Infect Dis 2001;32:108-15.
72. Centers for Disease Control and Prevention. Staphylococcus aureus resistant to vancomycin - United States, 2002. MMWR Morb Mortal Wkly Rep 2002;51:565-7.
73. Chang S, Sievert DM, Hageman JC, et al. Vancomycin-resistant Staphylococcus aureus investigative team. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003;348:1342-7.
74. Whitener CJ, Park SY, Browne FA, et al. Vancomycin-resistant Staphylococcus aureus in the absence of vancomycin exposure. Clin Infect Dis 2004;38:1049-55.
75. Centers for Disease Control and Prevention. Vancomycin-resistant Staphylococcus aureus - New York, 2004. MMWR Morb Mortal Wkly Rep 2004;53:322-3.
76. DSM Pharmaceuticals. Synercid (quinupristin-dalfopristin) package insert. Greenville, NC; 2003.
77. Clarebout G, Nativelle E, Bozdogan B, Villers C, Leclercq R. Bactericidal activity of quinupristin-dalfopristin against strains of Staphylococcus aureus with the MLS(B) phenotype of resistance according to the erm gene type. Int J Antimicrob Agents 2004;24:444-9.
78. Fuchs PC, Barry AL, Brown SD. Bactericidal activity of quinupristin-dalfopristin against Staphylococcus aureus: clindamycin susceptibility as a surrogate indicator. Antimicrob Agents Chemother 2000;44:2880-2.
79. Olsen KM, Rebuck JA, Rupp ME. Arthralgias and myalgias related to quinupristin-dalfopristin administration. Clin Infect Dis 2001;32:e83-6.
80. Carver PL, Whang E, VandenBussche HL, Kauffman CA, Malani PN. Risk factors for arthralgias or myalgias associated with quinupristin-dalfopristin therapy. Pharmacotherapy 2003;23;159-64.
81. Loeffler AM, Drew RH, Perfect JR, et al. Safety and efficacy of quinupristin-dalfopristin for treatment of invasive gram-positive infections in pediatric patients. Pediatr Infect Dis J 2002;21:950-6.
82. Gray JW, Darbyshire PJ, Beath SV, Kelly D, Mann JR. Experience with quinupristin-dalfopristin in treating infections with vancomycin-resistant Enterococcus faecium in children. Pediatr Infect Dis J 2000;19:234-8.
83. Ang JY, Lua JL, Turner DR, Asmar BI. Vancomycin-resistant Enterococcus faecium endocarditis in a premature infant successfully treated with linezolid. Pediatr Infect Dis J 2003;22:1101-3.
84. Werner G, Klare I, Spencker FB, Witte W. Intra-hospital dissemination of quinupristin-dalfopristin- and vancomycin-resistant Enterococcus faecium in a paediatric ward of a German hospital. J Antimicrob Chemother 2003;52:113-15.
85. Pharmacia & Upjohn. Zyvox (linezolid) package insert. Kalamazoo, MI; 2003.
86. Fines M, Leclercq R. Activity of linezolid against gram-positive cocci possessing genes conferring resistance to protein synthesis inhibitors. J Antimicrob Chemother 2000;45:797-802.
87. Saiman L, Goldfarb J, Kaplan SA, et al. Safety and tolerability of linezolid in children. Pediatr Infect Dis J 2003;22:S193-200.
88. Meissner HC, Townsend T, Wenman W, et al. Hematologic effects of linezolid in young children. Pediatr Infect Dis J 2003;22:S186-92.
89. Gerson SL, Kaplan SL, Bruss JB, et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother 2002;46:2723-6.
90. Thomas CR, Rosenberg M, Blythe V, Meyer WJ III. Serotonin syndrome and linezolid. J Am Acad Child Adolesc Psychiatry 2004;43:790.
91. Burleson BS, Ritchie DJ, Micek ST, Dunne WM. Enterococcus faecalis resistant to linezolid: case series and review of the literature. Pharmacotherapy 2004;24:1225-31.
92. Rahim S, Pillai SK, Gold HS, Venkataraman L, Inglima K, Press RA. Linezolid-resistant, vancomycin-resistant Enterococcus faecium infection in patients without prior exposure to linezolid. Clin Infect Dis 2003;36:E146-8.
93. Wilson P, Andrews JA, Charlesworth R, et al. Linezolid resistance in clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 2003;51:186-8.
94. Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001;358:207-8.
95. Mutnick AH, Enne V, Jones RN. Linezolid resistance since 2001: SENTRY antimicrobial surveillance program. Ann Pharmacother 2003;37:769-74.
96. Cubist Pharmaceuticals. Cubicin (daptomycin) package insert. Lexington, MA; 2003.
97. Alborn WE Jr, Allen NE, Preston DA. Daptomycin disrupts membrane potential in growing Staphylococcus aureus. Antimicrob Agents Chemother 1991;35:2282-7.
98. Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006;355:653-65.
99. Cubist Pharmaceuticals. Data on file. Lexington, MA; 2006.
100. Akins RL, Hasse MR, Levy EN. Pharmacokinetics of daptomycin in critically-ill adolescent with vancomycin-resistant enterococcal endocarditis. Pharmacotherapy 2006;26:694-8.
101. Silverman JA, Mortin LI, Vanpraagh AD, Li T, Alder J. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005;191:2149-52.
102. Oleson FB Jr, Berman CL, Kirkpatrick JB, Regan KS, Lai JJ, Tally FP. Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother 2000;44:2948-53.
103. Wyeth Pharmaceuticals. Tygacil (tigecycline) package insert. Philadelphia, PA; 2005.
104. Patel R, Rouse MS, Piper KE, Steckelberg JM. In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2000;38:177-9.
105. Muralidharan G, Micalizzi M, Speth J, Raible D, Troy S. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005;49:220-9.
106. Ruhe JJ, Monson TP. Use of tetracyclines for infections caused by methicillin-resistant Staphylococcus aureus. Presented at the 42nd annual meeting of the infectious diseases society of America, Boston, Massachusetts, September 30-October 3, 2004.
107. Weber SG, Gold HS, Hooper DC, Karchmer AW, Carmeli Y. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis 2003;9:1415-22.
108. Blumberg HM, Rimland D, Carroll DJ, Terry P, Wachsmuth IK. Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus. J Infect Dis 1991;163:1279-85.
109. Yee CL, Duffy C, Gerbino PG, Stryker S, Noel GJ. Tendon or joint disorders in children after treatment with fluoroquinolone or azithromycin. Pediatr Infect Dis J 2002;21:525-9.
110. Grady R. Safety profile of quinolone antibiotics in the pediatric population. Pediatr Infect Dis J 2003;22:1128-32.
111. Bayer Pharmaceuticals. Cipro (ciprofloxacin) package insert. West Haven, CT; 2004.
112. Lewis JS II, Jorgensen JH. Inducible clindamycin resistance in staphylococci: should clinicians and microbiologists be concerned? Clin Infect Dis 2005;40:280-5.
113. Kaplan SL. Treatment of community-associated methicillin-resistant Staphylococcus aureus infections. Pediatr Infect Dis J 2005;24:457-8.
114. Deville JG, Adler S, Azimi PH, et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. Pediatr Infect Dis J 2003;22:S158-63.
115. Kaplan SL, Deville JG, Yogev R, et al. Linezolid versus vancomycin for treatment of resistant gram-positive infections in children. Pediatr Infect Dis J 2003;22:677-86.
116. Yogev R, Patterson LE, Kaplan SL, et al. Linezolid for the treatment of complicated skin and skin structure infections in children. Pediatr Infect Dis J 2003;22:S172-7.
117. Conte JE Jr, Golden JA, Kipps J, Zurlinden E. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother 2002;46:1475-80.
118. Bernardo K, Pakulat N, Fleer S, et al. Subinhibitory concentrations of linezolid reduce Staphylococcus aureus virulence factor expression. Antimicrob Agents Chemother 2004;48:546-55.
119. Wargo KA, Eiland EH III. Appropriate antimicrobial therapy for community-acquired methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis 2005;40:1376-8.
120. Verma A, Dhawan A, Philpott-Howard J, et al. Glycopeptide-resistant Enterococcus faecium infections in paediatric liver transplant recipients: safety and clinical efficacy of quinupristin-dalfopristin. J Antimicrob Chemother 2001;47:105-8.
121. Saiman L, O'Keefe M, Graham PL III, et al. Hospital transmission of community-acquired methicillin-resistant Staphylococcus aureus among postpartum women. Clin Infect Dis 2003;37:1313-19.
122. Kourbatova EV, Halvosa JS, King MD, Ray SM, White N, Blumberg HM. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA 300 clone as a cause of health care-associated infections among patients with prosthetic joint infections. Am J Infect Control 2005;33:385-91.
123. Bratu S, Eramo A, Kopec R, et al. Community-associated methicillin-resistant Staphylococcus aureus in hospital nursery and maternity units. Emerg Infect Dis 2005;11:808-13.
124. Regev-Yochay G, Rubinstein E, Barzilai A, et al. Methicillin-resistant Staphylococcus aureus in neonatal intensive care unit. Emerg Infect Dis 2005;11:453-6.
125. Centers for Disease Control and Prevention. Guideline for hand hygiene in health-care settings: recommendations of the healthcare infection control practices advisory committee and the HICPAC/SHEA/APIC/IDSA hand hygiene task force. MMWR Morb Mortal Wkly Rep 2002;51:1-45.
126. Centers for Disease Control and Prevention. Campaign to prevent antimicrobial resistance in healthcare settings. Available from http://www.cdc.gov/drugresistance/healthcare/children/12steps_children.htm. Accessed January 12, 2006.
127. Muto CA, Jernigan JA, Ostrowsky BE, et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and Enterococcus. Infect Control Hosp Epidemiol 2003;24:362-86.
128. Jarvis WR, Ostrowsky B. Dinosaurs, methicillin-resistant Staphylococcus aureus, and infection control personnel: survival through translating science into prevention. Infect Control Hosp Epidemiol 2003;24:392-6.
129. McAnally TP, Lewis MR, Brown DR. Effect of rifampin and bacitracin on nasal carriers of Staphylococcus aureus. Antimicrob Agents Chemother 1984;25:422-6.
130. Loeb M, Main C, Walker-Dilks C, Eady A. Antimicrobial drugs for treating methicillin-resistant Staphylococcus aureus colonization. Cochrane Database Syst Rev 2003;(4):CD003340.